Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Medical College of Wisconsin Cancer Center Clinical Trials Office
CONTACT
Medical College of Wisconsin Cancer Center Clinical Trials Office, MD
CONTACT
Lead
Medical College of Wisconsin
Non-randomized, single arm, dose escalating, Phase I study evaluating the feasibility and safety of a novel anti-CD30 biAb-AATC product for adult patients with relapsed/refractory CD30+ cancer. Following T-cell collection patients are recommended to receive a bridging chemotherapy for 21 days while product is being generated and quality control assessed. Patients will then undergo weekly administration of dose escalating CD30 biAb-AATC infusions with twice weekly subcutaneous GM-CSF in 4-week cycles for a maximum of two total cycles.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
